Session » Systemic Lupus Erythematosus – Clinical Poster III: Treatment

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2677

A Systematic Review Examining the Association between Organ Damage and Health-Related Quality of Life in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2680

Activation Towards Health Self-Management in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2675

Age-Related Metabolic Changes Underlie Pro-Inflammatory Lineage Specification and Contribute to Therapeutic Responsiveness to Mechanistic Target of Rapamycin Blockade in SLE

9:00AM-11:00AM: Abstract Number: 2656

Apremilast As Treatment of Refractory Skin Lupus Lesions

9:00AM-11:00AM: Abstract Number: 2669

Assessing the Need for Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis in SLE Patients on Immunosuppression

9:00AM-11:00AM: Abstract Number: 2657

Assessment of Habitual Physical Activity and Performance during Maximal Exercise Test in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 2670

Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Systemic Lupus Erythematosus: A Retrospective Study

9:00AM-11:00AM: Abstract Number: 2642

Atacicept Dose Rationale for a Phase 3 Study in Patients with High Disease Activity and Auto-Antibody Positive SLE

9:00AM-11:00AM: Abstract Number: 2639

Bone Mineral Density Is Not Associated with Osteoporotic Fractures in Premenopausal Women and Men < 50 Years Old with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2662

Changes in Blood Pressure and Proteinuria at One Year in Two Lupus Nephritis Clinical Trials

9:00AM-11:00AM: Abstract Number: 2659

Clinical Features, Damage Accrual and Survival in Patients with Familial Systemic Lupus Erythematosus (SLE): Data from a Multiethnic, Multinational Latin American Lupus Cohort

9:00AM-11:00AM: Abstract Number: 2635

Combined Panel of Nine Tests Has the Greatest Sensitivity but the Lowest Specificity to Detect Antiphospholipid Antibody Syndrome in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2663

Comparison of Clinical and Laboratory Profiles in 3575 Systemic Lupus Erythematosus Patients with and without Sjögren’s Syndrome: Data from the Spanish Society for Rheumatology Lupus Registry

9:00AM-11:00AM: Abstract Number: 2647

Comparison of Low-Dose Intravenous Cyclophosphamide with Oral Mycophenolate Mofetil in the Treatment of Lupus Nephritis: Long Term Follow-up Data

9:00AM-11:00AM: Abstract Number: 2630

Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2653

Contraceptive Documentation in Systemic Lupus Erythematosus Patients at a Safety Net Hospital

9:00AM-11:00AM: Abstract Number: 2671

Development and First-in-Human Characterization of an ICOSL and BAFF Bispecific Inhibitor AMG 570 for SLE Treatment

9:00AM-11:00AM: Abstract Number: 2673

Different Risk Profiles for Development of Steroid-Related and Steroid-Unrelated Damage in Early Diagnosed SLE: Results from the Italian Multicenter Early Lupus Project Inception Cohort

9:00AM-11:00AM: Abstract Number: 2633

Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE

9:00AM-11:00AM: Abstract Number: 2646

Disparities in Antimalarial Prescribing for Systemic Lupus Erythematous Nephritis Using a Real-World, Electronic Health Record

9:00AM-11:00AM: Abstract Number: 2650

Efficacy, Safety, and Predictor of Response to Belimumab in a Large Nationwide Cohort Study of Patients with Active Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2652

Engaging the Cholinergic Anti-Inflammatory Pathway By Stimulating the Vagus Nerve Reduces Pain and Fatigue in Patients with SLE

9:00AM-11:00AM: Abstract Number: 2654

Exposure to Air Pollution and the Onset and Progression of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2679

Glucocorticoids Withdrawal in Systemic Lupus Erythematosus: Are Remission and Low Disease Activity Reliable Starting Points for Stopping Therapy? a Real-Life Experience

9:00AM-11:00AM: Abstract Number: 2640

Hematologic Activity in Systemic Lupus Erythematosus: Is Splenectomy Our Best Choice?

9:00AM-11:00AM: Abstract Number: 2628

Hydroxychloroquine and Prednisone Have Different Effects on Antiphospholipid Antibodies in SLE, with Hydroxychloroquine Not Reducing IgA Anticardiolipin

9:00AM-11:00AM: Abstract Number: 2668

Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2631

Hydroxychloroquine Blood Levels Are Significantly Associated with Cardiovascular Risk Factors

9:00AM-11:00AM: Abstract Number: 2641

Hydroxychloroquine Could Modulate S100 Proteins Expression, Which Reflect the Activity of Lupus Nephritis or Skin Lesion, in Systemic Lupus Erythematosus Patients with Low Disease Activity

9:00AM-11:00AM: Abstract Number: 2637

Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2674

Identifying Phenotype Clusters in Systemic Lupus Erythematosus By Damage Cluster

9:00AM-11:00AM: Abstract Number: 2644

Identifying Response for the Systemic Lupus Erythematosus Disease Activity Glucocorticoid Index (SLEDAI-2KG)

9:00AM-11:00AM: Abstract Number: 2678

Integrated Safety Profile of Atacicept from All Clinical Studies to Date

9:00AM-11:00AM: Abstract Number: 2685

Interferon-Inducible Gene Expression Kit As a Potential Diagnostic Test for Anifrolumab: Analytical Validation for Use in Clinical Trials

9:00AM-11:00AM: Abstract Number: 2636

Investigating Lupus Nephritis Patient Outcomes Receiving Belatacept Post Renal Transplant Using the UNOS Database

9:00AM-11:00AM: Abstract Number: 2664

Long-Term Clinical Outcomes in a Cohort of Adults with Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2629

Longitudinal Analysis of Persistent Positivity of Antiphospholipid Antibodies in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2660

Low-Dose Interleukin-2 Treatment of Refractory Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2681

Lupus Primary Care Management Practices

9:00AM-11:00AM: Abstract Number: 2661

Metformin Combined with Conventional Therapy Increases Absolute Number of Regulatory T Cells in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2627

Not All Clinical Responders in SLE Are Equal: Comparison of Subcutaneous Belimumab + Standard of Care Responders to Placebo + Standard of Care Responders

9:00AM-11:00AM: Abstract Number: 2682

Novel Antibody Against Commensal Bacterial Antigen in Prediction of the Response of Rituximab in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2651

Patients Characteristics and Patters of Treatment in Refractory Systemic Lupus Erythematosus Patients in the Pre-Biologic Period: Data from a Multiethnic, Multinational Latin American Lupus Cohort

9:00AM-11:00AM: Abstract Number: 2686

Podocyte Foot Process Width Is a Prediction Marker for Complete Renal Remission at 6 and 12 Months after Induction Therapy in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2649

Prevalence of Cancer in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2632

Rates and Predictors of Thirty-Day Readmission Among Patients Hospitalized for Systemic Lupus Erythematosus at a Single Tertiary Care Center

9:00AM-11:00AM: Abstract Number: 2658

Real World Medication Use in Incident Systemic Lupus Erythematosus and Lupus Nephritis Patients

9:00AM-11:00AM: Abstract Number: 2648

Relationship between Damage and Mortality in Juvenile-Onset Systemic Lupus Erythematosus: Cluster Analyses in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry

9:00AM-11:00AM: Abstract Number: 2683

Selective Expansion and Targeting of FoxP3+CD127lo Regulatory T Cells By Low-Dose IL-2 Therapy in Active SLE

9:00AM-11:00AM: Abstract Number: 2672

Serum Vitamin D Levels and Its Effect on Disease Activity and Fatigue in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 2676

SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment

9:00AM-11:00AM: Abstract Number: 2655

SLE-Key® Ruleout Testing in Support of Patient Triage in the Clinical Rheumatology Setting

9:00AM-11:00AM: Abstract Number: 2667

Sledai and Mex-Sledai Glucocorticoid Indices As Predictors of Damage and Mortality in Multinational Multiethnic Latin American Cohort

9:00AM-11:00AM: Abstract Number: 2643

Sledai-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2638

Tacrolimus Use in Hispanic Patients with Refractory Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2645

The Impact of Metformin on Disease Activity in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2634

The Risk of Hydroxychloroquine Retinopathy in an SLE Cohort: Screening and Prevention in Clinical Practice

9:00AM-11:00AM: Abstract Number: 2665

Treatment Trends of Systemic Lupus Erythematosus during Early-Years of the Disease

9:00AM-11:00AM: Abstract Number: 2666

Trends in Treatment of Systemic Lupus Erythematosus and Lupus Nephritis: 2006-2016

9:00AM-11:00AM: Abstract Number: 2684

Type I IFN, TLR7, MHC Class I, B Cell and OX40 Pathways Suppressed By Anifrolumab (anti-type I IFN receptor) in Moderate to Severe SLE Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].